What is Laplace Interventional?
Based in Plymouth, Minnesota, Laplace Interventional is a medical technology firm dedicated to addressing the clinical challenges of Tricuspid Regurgitation. The company is currently engineering a Transcatheter Tricuspid Valve Replacement (TTVR) system, a sophisticated medical device designed to provide a less invasive alternative to traditional open-heart surgery. By focusing on prosthetic valve delivery systems, Laplace Interventional aims to improve patient outcomes and life expectancy for those suffering from complex heart valve conditions. The company operates at the intersection of interventional cardiology and bioengineering, maintaining a rigorous focus on investigational research and regulatory milestones to bring its life-saving technology to the global market.
How much funding has Laplace Interventional raised?
Laplace Interventional has raised a total of $12.9M across 1 funding round:
Series B
$12.9M
Series B (2023): $12.9M with participation from JWC Ventures, Engage Venture Partners, ShangBay Capital, and Features Capital
Key Investors in Laplace Interventional
Engage Venture Partners
A venture capital firm that focuses on supporting high-growth companies in the healthcare and technology sectors through strategic capital and operational guidance.
ShangBay Capital
An investment firm specializing in early-to-growth stage life science and medical device companies, with a particular emphasis on cross-border innovation.
Features Capital
A venture capital group that provides financial backing and strategic resources to emerging companies within the medical technology and biotechnology industries.
What's next for Laplace Interventional?
With the recent infusion of capital, Laplace Interventional is poised to scale its research and development operations. The primary objective remains the advancement of its TTVR system through the necessary clinical trials and regulatory pathways. As the company transitions from early-stage development to more advanced clinical validation, the focus will likely shift toward optimizing manufacturing processes and preparing for potential commercialization. Investors are closely monitoring the firm's ability to navigate the complex regulatory landscape of the medical device industry, as successful clinical outcomes could significantly disrupt the current standard of care for tricuspid valve disease.
See full Laplace Interventional company page
